OakChart

Orasure Technologies Inc

OSURHealthcare·Medical Instruments & Supplies·USA·Micro·NASD·Nov 11 • 3:06 PM ET

3.54+0.21 (6.16%)
2026-11-11 21:07 CET
Market cap
229.67 USD m
Revenue, TTM
116.23 USD m
Net income, TTM
-48.51 USD m
Free cash flow, TTM
-49.62 USD m
EPS diluted, TTM
-0.69
P/E
-
Compare

Price

OSUR against its 20, 50 and 200-day averages
2050200beat
3.003.504.004.50772K1.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OSURclose 3.5420-day 3.7550-day 3.72200-day 3.553.5452w high

22.8% under the 52-week high of 4.58 on 17 Jun 2026. 52-week low 2.08 on 21 Nov 2025. Last 15 sessions, 33.5% high to low

Volume 0.98× normal · the line is the 50-bar volume average

Profile

OSUR
52-week range, 58% of the way up
2.084.58

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

IndexRUT
Employees501
IPONov 17, 1986
Beta1.08
ATR, 14d0.23
Rel volume0.98
Short float4.06%
Insider own6.61%
Inst own85.18%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap244.10M
Enterprise Value112.74M
Income-48.51M
Sales116.23M
Book/sh4.45
Cash/sh2.15
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees501
IPONov 17, 1986

Ratios

P/E-
Forward P/E-
PEG-
P/S2.10
P/B0.79
P/C1.65
P/FCF-
EV/EBITDA-
EV/Sales0.97
Quick Ratio7.36
Current Ratio8.58
Debt/Eq0.05
LT Debt/Eq0.05
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.69
EPS next Y-0.61
EPS next Q-0.17
EPS this Y36.70%
EPS next Y-3.36%
EPS next 5Y20.63%
EPS past 3/5Y-58.18% -33.45%
Sales past 3/5Y-33.29% -7.70%
EPS Y/Y TTM14.93%
Sales Y/Y TTM-7.53%
EPS Q/Q-1.06%
Sales Q/Q14.11%
EarningsNov 09 AMC
EPS/Sales Surpr.7.32% -0.30%

Ownership

Insider Own6.61%
Insider Trans1.67%
Inst Own85.18%
Inst Trans-2.23%
ROA-12.56%
ROE-14.50%
ROIC-15.07%
Gross Margin39.54%
Oper. Margin-59.70%
Profit Margin-41.73%
SMA20-5.72%
SMA50-5.00%
SMA200-0.30%
Trades-

Technical

Shs Outstand69.04M
Shs Float64.41M
Short Float4.06%
Short Ratio4.58
Short Interest2.61M
52W High4.58 -22.81%
52W Low2.08 69.96%
Volatility7.54% 5.98%
ATR (14)0.23
RSI (14)45.27
Beta1.08
Rel Volume0.98
Avg Volume570.04K
Volume484,585

Performance

Perf Week-4.97%
Perf Month-7.21%
Perf Quarter-12.06%
Perf Half Y16.29%
Perf YTD46.08%
Perf Year43.71%
Perf 3Y-45.28%
Perf 5Y-63.93%
Perf 10Y-57.46%
Recom2.00
Target Price5.50
Prev Close3.33
Price3.54
Change %6.16%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 03, 2023ResumedEEvercore ISIIn-line$5+41.4%
Sep 22, 2021DowngradeRRaymond JamesOutperform → Mkt Perform
Aug 21, 2020InitiatedEEvercore ISIOutperform$22+522.3%
Aug 10, 2020InitiatedJJP MorganNeutral$18+409.2%
Aug 10, 2020InitiatedCCitigroupBuy$18+409.2%
Aug 07, 2020UpgradeRRaymond JamesMkt Perform → Outperform$16+352.6%
Jun 25, 2020InitiatedLLake StreetBuy$19+437.5%
Apr 21, 2020ResumedSStephensEqual-Weight$14+296.0%
Oct 23, 2018ResumedRRaymond JamesMkt Perform
Jul 16, 2018DowngradeSStephensOverweight → Equal-Weight

Peers

Mkt cap
TickerCompanyMkt cap
QDELQuidelOrtho Corp807.92M
TRIBTrinity Biotech Plc ADR3.62M
BDXBecton Dickinson & Co58.11B
ABTAbbott Laboratories190.36B
CODXCo-Diagnostics Inc2.48M
BMRABiomerica Inc7.04M
DHRDanaher Corp165.51B
BIOBio-Rad Laboratories Inc10.41B
DGXQuest Diagnostics Inc28.43B
BJDXBluejay Diagnostics Inc3.01M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Boyd Steven KyleDirectorMay 13 '26Buy3.0225,00075,50088,462May 14 08:55 PM
Boyd Steven KyleDirectorMay 14 '26Buy2.9925,00074,750113,462May 14 08:55 PM
Boyd Steven KyleDirectorMay 12 '26Buy2.9825,00074,50063,462May 14 08:55 PM
McGrath Kenneth JChief Financial OfficerMar 20 '26Buy2.9332,30094,600589,562Mar 23 07:23 PM
EGLINTON MANNER CARRIEPresident & CEOMar 20 '26Buy2.9332,30094,5972,190,874Mar 23 07:23 PM
McGrath Kenneth JChief Financial OfficerMar 13 '26Buy3.0022,02166,030557,262Mar 16 08:01 PM
EGLINTON MANNER CARRIEPresident & CEOMar 13 '26Buy3.0022,02266,0332,158,574Mar 16 08:01 PM
Mara AspinallBoardDec 04 '25Proposed Sale2.5189,716225,000Dec 04 01:45 PM
Gagliano Nancy JDirectorNov 28 '25Buy2.372,1004,982160,254Dec 02 04:16 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M

News

latest 14 of 200
  • OraSure Beats On The Bottom Line, But A Delayed Cash-Breakeven Target Overshadows Margin Progress (Earnings Whispers) -5.67%
  • OraSure: Q3 Earnings Snapshot (Associated Press)
  • OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion (GlobeNewswire)
  • OraSure Must Prove Its Q2 Rebound Was More Than Fiscal-Year Buying (Earnings Whispers) -12.31%
  • OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care (GlobeNewswire)
  • OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th (GlobeNewswire)
  • OraSure Technologies Inc (OSUR) (Q2 2026) Earnings Call Highlights: Revenue Surges 9. ... (GuruFocus.com)
  • OraSure: Q2 Earnings Snapshot (Associated Press)
  • OraSure Announces Second Quarter 2026 Financial Results (GlobeNewswire)
  • OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th (GlobeNewswire) +6.33%
  • OraSure Receives Emergency Use Authorization for Second Generation Ebola Test (GlobeNewswire)
  • OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient-Friendly Access to Testing for Sexually Transmitted Infections (GlobeNewswire)
  • OraSure: Q1 Earnings Snapshot (Associated Press)
  • OraSure Announces First Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.190-0.205-0.19030.9131.002
2026Q22026-08-050.090-0.2700.08930.6429.101
2026Q12026-05-06-0.320-0.230-0.32127.9327.721
2025Q42026-02-25-0.270-0.205-0.27026.7226.442
2025Q32025-11-05-0.190-0.190-0.18827.0929.132
2025Q22025-08-05-0.260-0.205-0.26431.2430.362
2025Q12025-05-07-0.210-0.162-0.21429.9329.183
2024Q42025-02-25-0.140-0.055-0.14537.4536.813
2024Q32024-11-06-0.060-0.077-0.06039.9238.973
2024Q22024-08-06-0.010-0.008-0.00854.3452.344
2024Q12024-05-08-0.050--0.04954.1352.27-
2023Q42024-02-270.2700.1020.26875.8874.136
2023Q32023-11-070.1500.0580.15089.1974.566
2023Q22023-08-03-0.070-0.066-0.06585.4463.895
2023Q12023-05-100.3700.1580.368154.96123.066
2022Q42023-02-140.2100.0110.212123.0897.106

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY0.5100.4960.507167.06162.35
2018FY0.3300.2780.326181.74179.27
2019FY0.2700.3000.268154.61151.95
2020FY-0.220-0.168-0.221171.72166.11
2021FY-0.320-0.331-0.320233.67232.4
2022FY-0.250-0.480-0.236387.48357.21
2023FY0.7200.5430.721405.47403.82
2024FY-0.260-0.175-0.262185.83186.04
2025FY-0.940-0.865-0.940115.02114.7
2026FY--0.595--120.36
2027FY--0.615--131.24
2028FY--0.470--141.98

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1020130.8730.7431.00
2026Q4S2026-11-0920031.7031.0032.40
2026Q4S2026-10-2220031.7031.0032.40
2026Q4S2026-08-0610032.4032.4032.40
2026Q4S2026-07-3010032.4032.4032.40
2026Q4S2026-07-2120032.0731.7332.40
2026Q4S2026-05-0821032.0731.7332.40
2026Q4S2026-05-0721031.9231.7332.10
2026Q4S2026-04-1720031.1430.1932.10
2026Q4S2026-02-2631030.8430.1932.10
2026Q4S2026-01-2720030.7829.3632.19
2026Q4S2026-01-2120130.7829.3632.19
2026Q4S2025-11-1320230.7829.3632.19
2026Q4S2025-11-1120133.1832.1934.17

Estimate history

EPS, annual0.5070.3260.268-0.221-0.32-0.2360.721-0.262-0.935-0.6914
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.06-0.145-0.214-0.264-0.188-0.27-0.3210.089-0.19
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual167.064181.743154.605171.721233.674387.479405.472185.827115.021116.23
Period201720182019202020212022202320242025TTM
Sales, quarterly39.91537.44529.93131.24227.08526.76327.92530.63930.907
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual60.66261.27661.73171.73872.06972.73473.52874.59870.39169.036
Period201720182019202020212022202320242025MRQ
Shares, quarterly74.59374.59875.11473.73572.26570.39169.39768.96869.036
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue116.23115.02185.83405.47387.48233.67171.72154.60181.74
Cost of Goods Sold Incl. D&A70.2772.49109.60226.05239.04116.0769.8560.0268.13
Gross Profit45.9642.5376.23179.42148.44117.60101.8794.58113.61
Selling, General and Administrative Excl. Other115.35110.6696.83125.34153.68129.25107.7585.5974.35
Research and Development41.2640.4524.4233.1636.2434.1731.0319.6316.25
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-69.39-68.12-20.6054.08-5.24-11.65-5.889.0039.27
Interest Expense--------0.00
Unusual Expense-19.504.577.6521.3916.91-1.49-0.710.5310.84
Net Income Before Taxes-45.12-64.59-16.0056.26-15.68-9.29-3.5221.3331.72
Income Taxes0.541.801.802.601.4613.7111.404.6711.32
Consolidated Net Income-48.51-68.73-19.5053.66-17.13-23.00-14.9216.6620.40
Net Income From Continuing Operations-48.51-68.73-19.5053.66-17.13-23.00-14.9216.6620.40
Net Income-48.51-68.73-19.5053.66-17.13-23.00-14.9216.6620.40
EPS (Recurring)-0.90-0.89-0.190.92-0.07-0.33-0.230.270.45
EPS (Basic, Before Extraordinaries)-0.69-0.94-0.260.73-0.24-0.32-0.220.270.33
EPS (Diluted)-0.69-0.94-0.260.72-0.24-0.32-0.220.270.33
EBITDA-62.42-57.93-9.7373.988.760.013.5016.3445.72
Non-Operating Income (Expense)4.778.1112.2523.576.480.871.6512.873.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.958.029.428.489.185.705.212.9612.04
Price To Earnings Ratio--24.0012.33---30.0235.88
Price To Sales Ratio2.331.551.451.500.902.684.163.234.02
Gross Margin39.5436.9841.0244.2538.3150.3359.3261.1862.51
Operating Margin-59.70-59.23-11.0913.34-1.35-4.99-3.435.8221.61
Net Margin-41.73-59.76-10.4913.23-4.42-9.84-8.6910.7711.22
Shares Outstanding69.0470.3974.6073.5372.7372.0771.7461.7361.28
Market Capitalization229.67229.67269.29602.57350.04626.01759.29495.66715.70

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue30.9130.6427.9326.7627.0931.2429.9337.45
Cost of Goods Sold Incl. D&A18.2918.7217.4715.7916.7119.5519.0523.64
Gross Profit12.6211.9210.4610.9710.3711.6910.8813.80
Selling, General and Administrative Excl. Other24.8229.0733.6327.8226.0928.9829.1425.37
Research and Development7.289.2613.3011.429.5910.839.126.05
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.21-17.15-23.18-16.85-15.71-17.29-18.27-11.57
Unusual Expense0.00-22.570.092.980.380.730.480.85
Net Income Before Taxes-11.796.82-21.72-18.43-13.29-16.89-15.97-9.51
Income Taxes0.710.06-0.430.210.052.00-0.460.76
Consolidated Net Income-13.096.25-22.38-19.29-13.71-19.69-16.04-10.79
Net Income From Continuing Operations-13.096.25-22.38-19.29-13.71-19.69-16.04-10.79
Net Income-13.096.25-22.38-19.29-13.71-19.69-16.04-10.79
EPS (Recurring)-0.19-0.14-0.32-0.24-0.18-0.26-0.21-0.14
EPS (Basic, Before Extraordinaries)-0.190.09-0.32-0.27-0.19-0.26-0.21-0.14
EPS (Diluted)-0.190.09-0.32-0.27-0.19-0.26-0.21-0.14
EBITDA-10.01-14.78-20.84-16.79-13.26-14.77-15.46-11.47
Non-Operating Income (Expense)0.421.401.551.402.801.142.772.91
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.801.812.191.152.242.502.122.17
Price To Earnings Ratio-------24.00
Price To Sales Ratio2.332.781.851.511.861.611.561.45
Gross Margin40.8238.9137.4440.9838.2937.4236.3536.87
Operating Margin-39.50-55.98-82.99-62.97-58.02-55.35-61.02-30.90
Net Margin-42.3720.40-80.13-72.06-50.63-63.03-53.59-28.83
Shares Outstanding69.0468.9769.4070.3972.2773.7375.1174.60
Market Capitalization229.67307.06207.38173.60234.77224.40252.08269.29

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments199.28267.76290.41110.85153.04209.40156.34156.57155.90
Short Term Receivables22.2023.8240.1797.8145.3238.8436.9534.8442.52
Inventories31.0634.2047.6195.7053.1431.8623.1622.8919.34
Other Current Assets9.377.448.2720.8336.938.798.115.014.14
Total Current Assets261.91333.22386.46325.19288.43288.89224.55219.31221.91
Net Property, Plant & Equipment51.3258.6958.2771.1197.2256.3235.3424.3021.37
Total Investments and Advances25.9628.300.000.0017.0147.7233.4244.7520.69
Intangible Assets62.4157.7736.9046.8054.6258.2650.8823.6628.31
Deferred Tax Assets0.270.16-------
Other Assets1.301.531.221.093.713.295.123.553.93
Total Assets403.17479.66482.85444.18460.99454.47349.30315.57296.20
Short Term Debt Incl. Current Port. of LT Debt20.612.172.122.943.121.641.650.000.00
Accounts Payable6.528.1713.1538.0228.0217.419.5710.6010.23
Income Tax Payable------0.001.456.47
Other Current Liabilities12.6723.1424.2728.1036.9227.4421.5015.9415.54
Total Current Liabilities39.8033.4839.5469.0668.0646.4932.7127.9832.24
Long Term Debt20.3012.4311.399.609.154.495.580.000.00
Provision for Risks Charges0.000.000.000.000.352.050.110.003.51
Deferred Tax Liabilities--0.550.412.231.200.900.901.95
Other Liabilities2.2423.400.700.680.651.682.853.310.42
Total Liabilities62.3469.3252.1779.7580.4655.9042.1532.1938.12
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity340.83410.34430.67364.43380.53398.57307.14283.38258.08
Total Shareholders Equity340.83410.34430.67364.43380.53398.57307.14283.38258.08
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity340.83410.34430.67364.43380.53398.57307.14283.38258.08
Total Liabilities & Stockholders Equity403.17479.66482.85444.18460.99454.47349.30315.57296.20
Book Value Per Share4.845.505.865.015.285.564.984.624.25
Tangible Book Value Per Share3.964.735.364.374.524.744.154.243.79
Full-Time Employees501501638840785570472398377
Price to Book Ratio0.750.631.491.021.651.911.612.534.58
Return on Assets-15.57-4.0511.57-3.79-5.02-3.715.016.6712.28
Return on Equity-18.30-4.6413.51-4.60-5.90-4.235.647.5313.94
Return on Invested Capital-19.03-4.6112.14-4.58-5.90-3.705.337.2011.99
Quick Ratio5.808.938.573.323.465.536.167.026.28
Current Ratio6.589.959.774.714.246.216.867.846.88

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-48.51-68.73-19.5053.66-17.13-23.00-14.9216.6620.40
Depreciation9.3110.1910.8720.9415.3111.669.397.346.45
Other Funds (Non Cash)-6.3616.4217.8421.1428.3913.377.04-3.5515.61
Funds from Operations-43.43-40.268.5695.8324.923.051.1118.9941.54
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.26-8.7618.8245.76-72.12-38.444.69-9.19-2.45
Cash from Operating Activities-43.68-49.0227.37141.58-47.20-35.385.819.8039.09
Capital Expenditures-5.94-4.20-3.80-10.30-63.91-48.12-28.92-9.31-6.34
Net Assets From Acquisitions-3.61-3.61-5.040.000.000.00-3.04-23.800.00
Sale of Fixed Assets and Businesses0.131.000.000.000.120.000.0012.000.00
Purchase or Sale of Investments0.000.00-30.1927.7924.5442.1017.581.32-11.08
Purchase of Investments0.000.00-83.24-74.65-22.87-25.82-90.14-92.17-163.76
Sale Or Maturity of Investments0.000.0053.05102.4447.4167.92107.7293.49152.68
Other Uses0.000.000.000.000.00-0.020.000.000.00
Other Sources0.000.000.0048.6760.330.530.350.000.00
Cash from Investing Activities-9.42-6.81-39.0366.1521.09-5.50-14.03-19.80-17.43
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-11.99-15.04-3.33-1.63-2.24-1.8796.17-3.52-1.89
Repurchase of Common Pref Stock-12.04-15.04-3.55-1.90-2.25-2.11-2.09-3.71-3.59
Sale of Common Pref Stock0.050.000.210.270.010.2598.260.201.70
Proceedsfrom Stock Options0.000.000.000.000.000.0095.040.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.69-0.69-0.720.00
Change in Long Term Debt0.000.000.000.000.00-0.69-0.69-0.720.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.69-0.69-0.720.00
Net Financing Active Other Cash Flow-1.69-1.90-0.84-1.39-1.59-0.26-3.00-0.440.00
Other Financing Activities Uses-1.69-1.90-0.84-1.39-1.59-0.26-3.00-0.440.00
Cash from Financing Activities-13.68-16.94-4.18-3.02-3.83-2.8292.48-4.68-1.89
Exchange Rate Effect-1.464.29-6.821.71-2.84-0.340.831.95-4.20
Net Change in Cash-68.24-68.48-22.64206.43-32.78-44.0485.09-12.7215.57
Free Cash Flow-49.62-53.2223.58131.28-111.11-83.50-20.870.4932.75
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--11.404.65---1,018.8322.30
Deferred Taxes & Investment Tax Credit-1.85-0.660.10-1.651.03-0.39-1.46-0.92

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments148.24160.58176.96199.28216.48234.58
Short Term Receivables31.8227.3626.4122.2024.3025.90
Inventories30.4230.0730.3131.0633.4033.38
Other Current Assets4.824.927.099.378.837.58
Total Current Assets215.29222.94240.78261.91283.01301.44
Net Property, Plant & Equipment47.4349.8549.6151.3253.2055.04
Total Investments and Advances23.7524.3624.8725.9626.6026.97
Intangible Assets61.5061.5561.9962.4158.5259.01
Deferred Tax Assets0.140.450.640.270.210.00
Other Assets1.351.411.281.301.562.57
Total Assets349.47360.55379.17403.17423.10445.04
Short Term Debt Incl. Current Port. of LT Debt2.112.1520.9920.612.112.15
Accounts Payable7.778.4010.636.526.366.38
Other Current Liabilities15.2214.5712.4612.6731.7833.82
Total Current Liabilities25.1025.1244.0839.8040.2542.35
Long Term Debt14.7715.1819.4720.3011.3611.98
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.462.482.292.249.519.99
Total Liabilities42.3342.7765.8462.3461.1264.31
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity307.13317.78313.32340.83361.98380.72
Total Shareholders Equity307.13317.78313.32340.83361.98380.72
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity307.13317.78313.32340.83361.98380.72
Total Liabilities & Stockholders Equity349.47360.55379.17403.17423.10445.04
Book Value Per Share4.454.614.514.845.015.16
Tangible Book Value Per Share3.563.723.623.964.204.36
Full-Time Employees---501--
Price to Book Ratio0.750.990.620.480.620.57
Return on Assets-12.56-12.20-17.94-15.57-13.58-11.20
Return on Equity-14.50-14.07-21.16-18.30-15.30-12.65
Return on Invested Capital-4.071.88-6.72-5.34-3.67-5.01
Quick Ratio7.367.684.775.806.206.33
Current Ratio8.588.885.466.587.037.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-13.096.25-22.38-19.29-13.71-19.69
Depreciation2.202.372.342.402.462.53
Other Funds (Non Cash)3.54-19.223.785.543.244.82
Funds from Operations-7.02-10.40-16.61-9.41-7.28-12.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.850.482.710.41-2.792.56
Cash from Operating Activities-10.87-9.92-13.89-9.00-10.07-10.22
Capital Expenditures-1.67-2.43-0.91-0.92-0.92-1.94
Net Assets From Acquisitions0.000.000.00-3.610.000.00
Sale of Fixed Assets and Businesses0.000.020.000.110.100.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.67-2.41-0.91-4.42-0.82-1.94
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.05-2.00-5.00-5.04-3.28-5.78
Repurchase of Common Pref Stock0.00-2.00-5.00-5.04-3.28-5.78
Sale of Common Pref Stock0.050.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.08-0.25-1.28-0.07-1.80-0.01
Other Financing Activities Uses-0.08-0.25-1.28-0.07-1.80-0.01
Cash from Financing Activities-0.04-2.25-6.28-5.11-5.08-5.80
Exchange Rate Effect0.24-1.81-1.221.33-2.134.97
Net Change in Cash-12.34-16.38-22.31-17.20-18.10-12.99
Free Cash Flow-12.55-12.35-14.81-9.92-10.99-12.16

Revenue breakdown

C O V I D92024: 14.02M 2025: 13.76M
HCV2024: 3.51M 2025: 4.65M
HIV2024: 60.80M 2025: 49.80M
Molecular Products2024: 51.05M 2025: 38.36M
Molecular Services2024: 1.71M
Other Non Product Revenues2024: 1.22M 2025: 5.97M
Other Product And Services Revenues2024: 45.17M 2025: 624.00K
Risk Assessment Testing2024: 8.35M 2025: 1.87M
Africa2024: 32.75M 2025: 23.99M
Europe2024: 8.42M 2025: 7.39M
Other Foreign Countries2024: 5.50M 2025: 5.38M
United States2024: 139.16M 2025: 78.25M
Total Surgical & Medical Instruments & Apparatus revenue2024: 185.83M 2025: 115.02M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.06%2.6M64.4M558.19K
2026-10-154.24%2.7M64.4M496.30K
2026-09-304.55%2.9M64.4M478.99K
2026-09-154.93%3.2M64.4M492.38K
2026-08-314.86%3.1M64.4M525.81K
2026-08-144.88%3.1M64.4M605.48K
2026-07-314.61%3.0M64.3M642.53K
2026-07-155.08%3.3M64.3M645.06K
2026-06-304.62%3.0M64.3M633.55K
2026-06-154.79%3.1M64.3M616.68K
2026-05-294.41%2.8M64.5M575.86K
2026-05-154.74%3.1M64.8M524.76K
2026-04-304.49%3.0M67.1M466.65K
2026-04-155.01%3.2M64.5M490.25K
2026-03-315.26%3.4M65.2M539.79K
2026-03-135.40%3.5M65.2M554.81K
2026-02-275.65%3.8M67.6M576.11K
2026-02-135.94%4.0M67.6M665.03K
2026-01-305.75%3.9M67.6M684.17K
2026-01-155.85%4.0M67.6M683.96K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.003.101.2517.54220.000.000.809-0.0400.002
call5.000.002.150.1012.0581120.000.779-0.1130.002
call7.500.002.150.0013.6940.000.000.765-0.1320.002
put2.500.000.400.054.5712020.00-0.191-0.0390.002
put5.001.002.151.555.20340.000.00-0.221-0.1130.002
put7.502.306.100.0013.9470.000.00-0.238-0.1320.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09SCHEDULE 13G/ASEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-17SCHEDULE 13DSEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-06SEC
2026-08-12SCHEDULE 13GSEC
2026-08-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13G/ASEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-038-KCurrent report2026-06-03SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-143Initial statement of beneficial ownership of securities2026-04-16SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-04-30SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05224.75K300
2026-040000
2026-03321.26K400
2026-020000
2026-010000
2025-120000
2025-114.98K100

Institutional holders

Manager% owned
BlackRock, Inc.9.09%
Neuberger Berman Group LLC6.81%
Altai Capital Management, L.P.5.25%
PRIVATE MANAGEMENT GROUP INC4.61%
VANGUARD CAPITAL MANAGEMENT LLC4.38%
SYSTEMATIC FINANCIAL MANAGEMENT LP4.15%
DIMENSIONAL FUND ADVISORS LP3.27%
ACADIAN ASSET MANAGEMENT LLC2.93%
RENAISSANCE TECHNOLOGIES LLC2.93%
GAGNON SECURITIES LLC2.65%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.12%
iShares Russell 2000 ETF2.54%
First Eagle Small Cap Opportunity Fund1.70%
Neuberger Intrinsic Value Fund1.60%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Small Cap Index Fund1.04%
iShares Russell 2000 Value ETF0.87%
U.S. SMALL CAP VALUE PORTFOLIO0.86%
BlackRock Advantage Small Cap Core Fund0.65%
VANGUARD RUSSELL 2000 INDEX FUND0.54%

OakChart. OSUR. Cached 15 minutes.